The biopharmaceutical company, founded in 2011, uses its Insights-to-Validation Platform and proprietary chemical library to develop therapeutic compounds and combination therapies that target molecular aberrations and emerging resistance mechanisms in cancer. Blueprint Medicines has a small molecule drug pipeline in cancer and rare genetic diseases, with approved medicines delivered directly to patients in the US and Europe. The company's precision therapy approach aims to create medicines that selectively target genetic drivers, with ongoing programs for systemic mastocytosis, lung cancer, and other genomically defined cancers. Blueprint Medicines values transparency, curiosity, and diversity in its culture, with a commitment to making a profound impact on patients' lives.